In response to a significant ongoing disruption to the supply of Venlafaxine 37.5mg modified-release tablets, a Serious Shortage Protocol (SSP) has been issued by the Department of Health and Social Care (DHSC). Effective today 23rd June 2025, SSP083, provides that for every Venlafaxine 37.5mg modified-release tablet originally prescribed one Venlafaxine 37.5mg modified-release capsule must be supplied. SSP083,
Read moreLPC Chairs and Community Pharmacy England have met with MPs to discuss the value that pharmacies bring to local communities, as well as ways to address the continued pressures facing the sector. The Forum of LPC Chairs held in Parliament this week focussed on efforts to build an ever-stronger local voice for community pharmacy, including
Read moreWith the conclusion of the NHS 10-Year Health Plan imminent, this is a critical time for community pharmacy and it is important that we focus on the future, including looking at negotiating priorities to further leverage community pharmacy’s position. Pharmacy owners across the East of England and East and North Midlands are invited to ‘Future
Read moreThe Department of Health and Social Care (DHSC) has issued a medicine supply notification for the following products: Buprenorphine (Relevtec®) 35micrograms/hour, 52.5micrograms/hour, 70micrograms/hour transdermal patches Buprenorphine (Bupeaze®) 52.5micrograms/hour transdermal patches MSN/2025/038 Tier 2 – medium impact Date of issue: 19/06/2025 Buprenorphine (Relevtec®) 35micrograms/hour, 52.5micrograms/hour and 70micrograms/hour transdermal patches are out of stock until early August
Read moreThe Department of Health and Social Care (DHSC) has today (19/06/2025) confirmed the following initial list of price concessions for June 2025: Drug Pack size Price concession Alfuzosin 2.5mg tablets 60 £6.21 Amiodarone 200mg tablets 28 £2.39 Betamethasone 500microgram soluble tablets sugar free 100 £36.00 Clarithromycin 125mg/5ml oral suspension 70 £6.08 Clarithromycin 250mg/5ml oral suspension 70
Read moreFollowing on from last week’s Spending Review announcement, Community Pharmacy England has joined forces with other national primary care bodies to reiterate our call on Government to prioritise DHSC spending allocations towards primary care. The joint statement, copied below, has been signed by Community Pharmacy England, the General Practitioner’s Committee England, the British Dental Association’s
Read moreThe Department of Health and Social Care (DHSC) has issued a medicine supply notification for the following products: Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens Levemir® Penfill® 100units/ml solution for injection 3ml cartridges MSN/2025/036 Tier 2 – medium impact Date of issue: 16/06/2025 Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection
Read moreDepartment of Health and Social Care (DHSC) has issued a medicine supply notification for Venlafaxine 37.5mg modified-release tablets. MSN/2025/035 Tier 2 – medium impact Date of issue: 13th June 2025 Venlafaxine 37.5mg modified release (MR) tablets are out of stock until mid-July 2025. Venlafaxine 37.5mg MR capsules remain available and can support increased demand. Venlafaxine
Read moreWith the conclusion of the NHS 10-Year Health Plan imminent, this is a critical time for community pharmacy and it is important that we focus on the future, including looking at negotiating priorities to further leverage community pharmacy’s position. Pharmacy owners across Yorkshire and the Humber and the North East are invited to ‘Future of
Read more
MHRA Class 2 Medicines Notification: Inhixa 12,000IU (120mg)/0.8mL solution for injection (Maxearn Limited) Drug alert number: EL(25)A/27 Date issued: 12 June 2025 Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton.
Read more
